CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Accumulated Expenses data on file, last reported at $74.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 11.44% year-over-year to $74.9 million; the trailing twelve-month figure through Mar 2026 stood at $74.9 million (down 11.44% YoY), and the FY2025 full-year result was $13.0 million, down 68.43% from the prior year.
• Accumulated Expenses rose to $74.9 million in Q1 2026, from $13.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $103.0 million in Q3 2022 to a low of $8.6 million in Q2 2025.
• A 5-year average of $54.5 million and a median of $66.4 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 875.3% in 2023 and plunged 90.62% in 2025, its largest moves.
• Tracing CRSP's Accumulated Expenses over 5 years: stood at $19.2 million in 2022, then retreated by 9.84% to $17.3 million in 2023, then surged by 136.77% to $41.1 million in 2024, then plunged by 68.43% to $13.0 million in 2025, then soared by 477.91% to $74.9 million in 2026.
• Business Quant data shows CRSP's Accumulated Expenses at $74.9 million in Q1 2026, $13.0 million in Q4 2025, and $84.2 million in Q3 2025.